Antiviral Drug Remdesivir: The Relationship Between Patent Protection And Right to Health

Must Read

An Insight into Custodial Death in India

“The occurrence of Custodial deaths in the world’s greatest democracy has raised the eyebrows of every citizen and shaken...

Implications in Travel Insurance in Light of the COVID-19 Crisis

As the world, today is crippled by this once in a century pandemic and as of date more than...

Second-Round Effects of Rent Control Laws: The Argentine Case

Introduction In colonial India, a city had an issue with its cobra population, which was a problem clearly in need...

Why Are the Big Techs of Silicon Valley Accused of Anti-Competitive Behaviours?

The big tech giants of the Silicon Valley are facing major challenges with relation to their monopolistic powers after...

KSK announces Sanjay Kumar as a Partner for Pharma & Life Sciences Practice

New Partner for KSK's Pharma & Life Sciences Practice King Stubb & Kasiva recently announced that Mr Sanjay Kumar has...

The Debate Between IPR and Competition Law Explained

There are various market processes or structures that govern market scenario. For simplicity, this paper focuses on two mechanisms:...

Follow us

The COVID-19 surge is getting worse. The Union Health Ministry, via its revised Protocol, has recommended Remdesivir. This is an antiviral drug that is a possibly effective treatment for COVID-19. The greatest tussle is always between affordability and accessibility. Should the public Health get priority over patent protection in the present scenario? Since Remdesivir is an effective treatment against COVID-19, should its patent be revoked? 

Understanding the Issue

On April 9, 2020, the Cancer Patients Aid Association wrote a letter to the Union Health Ministry. In it, they demanded patent revocation for Remdesivir. The application claimed revocation on the grounds of public interest under Section 66 of the Patents Act, 1970. The application stated that the patent lacks novelty and an inventive step. Both are grounds for post-grant opposition. The previous judgments which invoked Section 66 were on different grounds. One was that the patent was prejudicial to farmers’ rights. Another was that it formed a part of traditional knowledge.

Revoking Remdesivir patent could enervate the patent framework in India. Possible alternatives to the revocation are compulsory licensing and a patent pool. Compulsory licensing has worked well in Italy. Nevertheless, four pharma companies have signed voluntary licensing agreements with Gilead Sciences. Gilead Sciences Inc. is the original drug manufacturer for Remdesivir.  This trend suggests that India does not want to indulge in unnecessary politics. 

Why Remdesivir?

The fight over patent ownership gets intensified if one looks at the Cell Research Paper. This paper has suggested Remdesivir as an effective drug against COVID-19. Seven scientists from Wuhan and three from Beijing are responsible for writing it. Wuhan Institute of Virology has also applied for a patent for Remdesivir. This application was on the basis of second medical use. Chinese Patent law permits this kind of use. Criticising this tussle is not the way out because Remdesivir was a public-funded drug. 

Further, Sanofi’s Plaquenil (earlier used for SARS) has also treated a Japanese patient. Other drugs have also proved useful. However, no drug is a sure treatment against COVID-19. In such a scenario, should grant of a patent be prioritised over public health?

Nevertheless, if patentability is not that important, will COVID-19 render patent law sterile? The best possible alternative is to pay heed to public Health. Even so, patent protection is also necessary. 

Compulsory Licensing: An Alternative to Section 66

Compulsory licensing has proven to be an alternative to revocation of patents. The revocation of patents could be susceptible to controversies. Italy has adopted a compulsory licensing model. With fixation of a reasonable royalty, compulsory licensing can bring the required equilibrium. At this stage, where public Health is of exemplary importance, this model can take care of the clash. Countries like Israel and Ecuador have also implemented this model.

With a stark rise in demand, the affordability of medicines is another challenge. The public health criterion makes it essential to make drugs affordable. This alternative is best for countries which are cash-stripped. In Indian Patent Law, a precondition to this is a government notification.  At times, due to political pressures, governments are not in a position to grant these. 

Does India have Requisite Know- How?

Certain technical limitations exist with breaking patents. Extensive know-how is a prerequisite when it comes to patents. Where public health is at stake, Sections 92, 101, and 103 should be exercised with caution. For medical technologies, it may be a hassle. India’s pharmaceutical know-how is quite weighty. Bulk procurement and technology transfer agreements could also be helpful. 

Right to Health (Rth) Framework for Patent Policy

Access to medical aid is well within the realms of Right to Health under Article 21 of the Constitution. The Government also has positive obligations towards securing RtH of the patients. Provisions of masks, sanitisers, hazmat suits all fall under its duty, especially in cases of non-affordability or unavailability. Securing public Health at the cost of patent infringement could be fine. However, the reverse could render patent law hollow. 

This approach is also enshrined in General Comment No. 14 of ICESCR. Paragraph 37 of the comment notes that state parties should take positive steps. These steps should be towards securing the Right to Health. Moreover, this framework should be the basis for patent law. As innovation is of no use unless put to public usage.

Patent Pooling

Costa Rica had suggested patent pooling on the pillars of solidarity and collaboration. Unbiased access to medicines and other COVID-19 related technology is of utmost importance. Patent pooling will create a platform for pooling data. It will also pool knowledge, and patents to deliver health goods. To ensure affordability and accessibility, this information will be accessible to all. Patent pooling can act as a game-changer. It could bring in efficiency and improve collaboration. It will also help lessen transactional costs. The voluntary nature of patent pooling enables governments to give incentives. These may be tax breaks and providing R& D support to companies. In these times, pharma companies should develop a collaborative aptitude. 

Due to accessibility concerns, patients have also started importing Remdesivir from Bangladesh. Bangladesh can manufacture the same due to its exemption from TRIPS. The Drugs Controller General of India is still awaiting test results. Post this, they will issue approval to the Bangladeshi companies. 

However, the affordability concerns cannot abate by importing at individual levels. Right to Health is a fundamental right and available to all. The RtH framework is a must in these trying times.

 According to Ms Harshada Wadkar, a Senior Associate at Lex Orbis:

“Due to the global pandemic, the Government enforced a countrywide lockdown in March. Since then, IP offices are functioning remotely. Notices for extension are also issued. Along with the extension of deadlines, policy guidelines are also required. Fast-tracking of applications providing a particular solution can also be inspiring.” 

 Accordingly, practical measures and the RtH framework will strengthen the patent fabric. 

Conclusion and Recommendations

The pandemic has resulted in patent battles. Concerns of patent protection while ensuring public Health have increased. As the virus spreads, countries facing a financial crunch must look for alternatives. Patent law would remain hollow if not used for public welfare. The Right to Health framework is the best patent policy. 

Patent pooling through international collaboration can also prove to be useful. PPP patent pooling is also an effective way. Doha Declaration under TRIPS promotes patent pooling Also, Seagate technology has signed a Pledge. This Pledge is the Open COVID Pledge. Under this, it provides free access to its patent technology for diagnosis. Seagate has also announced the’Data4Good’ program. This enables employees to contribute their skills and expertise.

Another plausible solution could be a patent buy out. This is when the Government acquires the patent and gives it out in the public domain. A system of auction can help reach a fair price. The Government pays the highest bid. Also, a mark-up will incentivise the technology for a social cause. Patent experts are also required to figure out the authenticated patents. This will avoid low-quality patents.

 This way, patents can get secured without any compromise on public Health.


Libertatem.in is now on Telegram. Follow us for regular legal updates and judgements from the court. Follow us on Google News, InstagramLinkedInFacebook & Twitter. You can also subscribe for our Weekly Email Updates. You can also contribute stories like this and help us spread awareness for a better society. Submit Your Post Now.

Latest News

Delhi HC: Mens Rea Essential Before Passing an Order U/S 14b of EPF Act

  In the matter of M/s Durable Doors and Windows v APFC, Gurugram, the bench allowed the Petitioner's appeal holding that mens rea is an...

Delhi HC: Language of Statement and Testimony of Complainant Need Not Be Identical

A single-judge bench of J. Vibhu Bakhru of the Delhi High Court upheld the accused's conviction in Kailash @ Balli v State. The bench...

COVID Results Shall Be Conveyed To the Person Within 24 Hours: Delhi High Court

The order has come in a writ petition moved by Rakesh Malhotra. The Petitioner herein seeks to ramp up testing facilities in Delhi.   Facts of...

Delhi High Court Sets Aside the Order of the Trial Court in the Chief Secretary Assault Case

In the case of Mr. Arvind Kejriwal & Anr. V. State NCT of Delhi, Mr.Justice Suresh Kumar Kait has set aside the 24.07.2019 Order...

Delhi High Court Temporarily Restrains Vintage Moments’ Alcohol Sale in Case of Trademark Infringement

The manufacturers of the Alcohol Brand Magic Moments had filed a suit. The Delhi High Court has passed an order restraining the manufacturing, marketing,...

NGT Red-Flags Kaleshwaram Project: Green Clearance Violated the Law, Halt Work

Excerpt The National Green Tribunal (NGT), Principal Bench, dated 20th October 2020, directed the Telangana government to stop all work, except the drinking water component...

There Can Be No Leniency Shown To Appellant Who Pleaded To Reduce Sentence: Delhi High Court

Facts On 25.2.2016 the victim’s sister who was 13 years old was present with her sister who was 2 years old (victim) at their home....

Violation of Executive Instructions Cannot Be Sole Ground to Invalidate Transfer Orders: Tripura High Court

In Dr Bithika Choudhury vs the State of Tripura & Ors., a Division Bench consisting of Hon’ble Justice S. Talapatra and Hon’ble Justice S.G. Chattopadhyay...

Case Regarding Anticipatory Bail, Applicant May Be Released Imposing Suitable Conditions: Gujarat High Court

A Single-Judge Bench of Gujarat High Court consisting of Honourable Dr Justice A.P. Thakur had been hearing submissions of the Applicant to release him...

Proof of Infliction of Fatal Injury Not Mandatory for Conviction Under Section 307, IPC: Tripura High Court

In the case of Mamin Miah vs the State of Tripura, a Division Bench consisting of Hon’ble Justice S. Talapatra and Hon’ble Justice S....

More Articles Like This

- Advertisement -